Tibet Pharmaceutical (600211.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 7.0 during the reporting period...
According to the Zhitong Finance App, Tibet Pharmaceutical (600211.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 704 million yuan, a year-on-year decrease of 22.35%; net profit to mother was 313 million yuan, an increase of 3.21%; after deducting non-net profit of 235 million yuan, a year-on-year decrease of 19.75%. Basic earnings per share were $1.26.